BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 25605343)

  • 1. [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].
    Rouprêt M; Malavaud B; Molinier L; Leleu H; Blachier M; Marteau F
    Prog Urol; 2015 Apr; 25(5):256-64. PubMed ID: 25605343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden.
    Malmström PU; Hedelin H; Thomas YK; Thompson GJ; Durrant H; Furniss J
    Scand J Urol Nephrol; 2009; 43(3):192-8. PubMed ID: 19330681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation.
    Garfield SS; Gavaghan MB; Armstrong SO; Jones JS
    Can J Urol; 2013 Apr; 20(2):6682-9. PubMed ID: 23587507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
    Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
    BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Is a routine second transurethral resection of the bladder still necessary after hexaminolévulinate photodynamic diagnosis-assisted TURBT?].
    Doisy L; Walz J; Fakhfakh S; Rybikowski S; Koskas Y; Gravis G; Pignot G
    Prog Urol; 2019; 29(6):332-339. PubMed ID: 31104952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit.
    Ahmad S; Aboumarzouk O; Somani B; Nabi G; Kata SG
    BJU Int; 2012 Dec; 110(11 Pt B):E596-600. PubMed ID: 22758907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III.
    Bach T; Bastian PJ; Blana A; Kaminsky A; Keller S; Knoll T; Lang C; Promnitz S; Ubrig B; Keller T; Qvick B; Burger M;
    World J Urol; 2017 May; 35(5):737-744. PubMed ID: 27578233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB.
    Todenhöfer T; Maas M; Ketz M; Kossack N; Colling C; Qvick B; Stenzl A
    World J Urol; 2021 Aug; 39(8):2953-2960. PubMed ID: 33569642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
    Capece M; Spirito L; La Rocca R; Napolitano L; Buonopane R; Di Meo S; Sodo M; Bracale U; Longo N; Palmieri A; Fusco F; Verze P; Califano G; Crocetto F; Imbimbo C; Mirone V; Imperatore V; Creta M
    Arch Ital Urol Androl; 2020 Apr; 92(1):17-20. PubMed ID: 32255316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HELENA study: Hexvix
    Gierth M; Breyer J; Zeman F; Fritsche HM; Cordes J; Karl A; Zaak D; Stenzl A; von Schmeling IK; Sommerhuber A; Zierer T; Burger M; Mayr R
    World J Urol; 2021 Oct; 39(10):3799-3805. PubMed ID: 34002265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
    Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
    Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis of management of low-risk non-muscle-invasive bladder cancer using office-based fulguration.
    Al Hussein Al Awamlh B; Lee R; Chughtai B; Donat SM; Sandhu JS; Herr HW
    Urology; 2015 Feb; 85(2):381-6. PubMed ID: 25623694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis.
    Burger M; Zaak D; Stief CG; Filbeck T; Wieland WF; Roessler W; Denzinger S
    Eur Urol; 2007 Jul; 52(1):142-7. PubMed ID: 17267099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden.
    Dansk V; Malmström PU; Bläckberg M; Malmenäs M
    Future Oncol; 2016; 12(8):1025-38. PubMed ID: 26975197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical results of the transurethreal resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid.
    Filbeck T; Roessler W; Knuechel R; Straub M; Kiel HJ; Wieland WF
    J Endourol; 1999 Mar; 13(2):117-21. PubMed ID: 10213106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovations in the endoscopic management of bladder cancer: is the era of white light cystoscopy over.
    Soria F; Gurioli A; Peraldo F; Oderda M; Giona S; Ambrosini E; Frea B; Gontero P
    Urologia; 2013 Jun; 80 Spec No 1():1-8. PubMed ID: 23813287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bladder tumor targeting by Hexvix(®) fluorescence: 4 years results after prospective monocentric evaluation].
    Ferré A; Cordonnier C; Demailly M; Hakami F; Sevestre H; Saint F
    Prog Urol; 2013 Mar; 23(3):195-202. PubMed ID: 23446284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors.
    Filbeck T; Pichlmeier U; Knuechel R; Wieland WF; Roessler W
    J Urol; 2002 Jul; 168(1):67-71. PubMed ID: 12050494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.